Certara acquired Integrated Nonclinical Development Solutions (INDS) for $8.0 million, a transaction completed in January 2022.
Integrated Nonclinical Development Solutions (INDS) operates in Software / Services. Integrated Nonclinical Development Solutions (INDS) provides the SEND Explorer software together with drug-development consulting. SEND (Standard for Exchange of Nonclinical Data) is a CDISC standard for submitting nonclinical study data to regulators, so the deal extended Certara's regulatory data-standardization footprint into the nonclinical (preclinical) domain. Certara completed the acquisition for total consideration of approximately $8.0 million; the transaction was not significant to its consolidated financial statements.
Extend Certara's regulatory data-standardization capability into nonclinical study data submission.
Advisory firms were not disclosed for this transaction.